<DOC>
	<DOCNO>NCT00399048</DOCNO>
	<brief_summary>The purpose study characterize effectiveness safety OROS hydromorphone HCL OxyContin patient chronic osteoarthritis ( OA ) knee hip receive chronic nonsteroidal anti-inflammatory drug ( NSAID ) nonsteroidal , non-opioid analgesic ( ie , acetaminophen aspirin ) therapy .</brief_summary>
	<brief_title>An Effectiveness , Safety Quality Life Measures With Hydromorphone HCL , Dilaudid CR ( Controlled Release )</brief_title>
	<detailed_description>This multicenter , open-label , randomize ( patient assign different treatment base chance ) , dose-titration , parallel-group study characterize effectiveness safety OROS hydromorphone HCL OxyContin adult patient osteoarthritis ( OA ) knee hip unable consistently control treat osteoarthritis pain non opioid medication as-needed use opioid analgesic . The study consist 14-day period randomization , dose-titration , stabilization , follow 4-week maintenance phase . Eligible patient randomize equally begin therapy either OROS hydromorphone HCL 8 mg daily OxyContin 10 mg twice daily . Upward dose titration ( dose increase titration ) start dos allow every 2 day , base pain relief opioid-related side effect . The dose titrate provide best balance pain relief side effect . After 14 day , therapeutic efficacy dose stabilization document , patient allow begin 4-week maintenance phase . The expected primary efficacy variable endpoint : The mean pain relief score endpoint define mean last 2 non miss pain relief score Maintenance Phase , day study medication initiation third day moderate complete pain relief patient 's final titrate dose ( report patient diary ) Randomization , Titration Stabilization Phase . Safety evaluate adverse event ( AEs ) , vital sign , physical examination . OROS hydromorphone HCL 8mg tablet orally daily OxyContin 10mg tablet orally daily ; Upward dose titration start dos allow every 2 day , base pain relief opioid-related side effect ; After 14 day efficacy dose stabilization , patient allow begin 4 week maintenance phase .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Patient meet criterion ( functional Class IIII hip knee ) osteoarthritis least 3 month enrollment Patient moderate severe chronic pain despite regular use stable dos NSAID ( nonsteroidal antiinflammatory drug ) NSAID opioid analgesic take needed daily basis treatment osteoarthritis . Patient intolerant hypersensitive hydromorphone oxycodone Patient childbearing potential must use medically recognize contraceptive program study Pregnant breastfeeding Patient prior joint replacement target knee hip Patient significant respiratory compromise depress ventilatory function Patient know active drug abuser alcoholic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Pain</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>knee Osteoarthritis</keyword>
	<keyword>hip Osteoarthritis .</keyword>
</DOC>